The short version of glucagon receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-11 and is reviewed periodically as new material appears.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
== AFL career == Colyer played his first AFL game against Carlton in round 3 of the 2010 AFL season. Colyer, along with 33 other Essendon players, was found guilty of using a banned performance enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his team-mates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 AFL season. The 2017 AFL season saw Colyer have one of his best seasons to date, playing 22 of a possible 23 games and averaging 17 disposals and four marks a game. Colyer had a frustrating start to 2018 missing half of the 2018 AFL season due to an ankle injury, which required surgery. He made his return for Essendon in round 15 playing eight of the final nine games. On 17 October 2018, in the final minutes of the 2018 AFL Trade Period, Colyer was traded to the Fremantle Football Club, for a future fourth-round selection, after nine seasons and eighty-seven games with Essendon. The 2021 AFL season saw Colyer have a career best season in which he played every game and kicked fifteen goals. Colyer signed a one-year contract extension at the end of the 2021 tying him to Fremantle until at least 2022.
Scattering data is usually represented in terms of the so-called excess Rayleigh ratio defined as the Rayleigh ratio of the solution or single particle event from which is subtracted the Rayleigh ratio of the carrier fluid itself and other background contributions, if any. The Rayleigh Ratio measured at a detector lying at an angle θ and subtending a solid angle ΔΩ is defined as the intensity of light per unit solid angle per unit incident intensity, I0, per unit illuminated scattering volume ΔV. The scattering volume ΔV from which scattered light reaches the detector is determined by the detector's field of view generally restricted by apertures, lenses and stops. Consider now a MALS measurement made in a plane from a suspension of N identical particles/molecules per ml illuminated by a fine beam of light produced by a laser. Assuming that the light is polarized perpendicular to the plane of the detectors. The scattered light intensity measured by the detector at angle θ in excess of that scattered by the suspending fluid would be
=== P. s. pv. actinidiae === Mesarich et al. 2017 provides several libraries for transposon insertion sequencing of mutants of P. s. a. The kiwifruit industry in New Zealand has suffered catastrophic losses since their first known outbreak in 2007 from P. syringae pv. actinidiae. New Zealand is second to Italy in the total volume of kiwifruit exports making an annual revenue of $NZ 1 billion, making it the most economically valuable export in the country. In 2014 the loss of exports alone was as high as NZ$930 million. Growers had to pay for treatments, and removal of infected vines along with suffering the loss of capital value in their orchards. For some, the orchard values went from NZ$450,000/ha to $70,000/ha after the outbreak, which is the price of bare land. The total loss of equity for the country of New Zealand was as high as NZ$2 billion. Between 2010 and 2012 over 2,000 hectares (4,900 acres) of Italian kiwifruit orchards either were killed by P. syringae pv. actinidiae or were killed to contain the disease. The financial consequences for growers and their suppliers were severe, as were the economic consequences more widely.
=== Pharmacodynamics === Most SNRIs function alongside primary metabolites and secondary metabolites in order to inhibit reuptake of serotonin, norepinepherine, and marginal amounts of dopamine. For example, venlafaxine works alongside its primary metabolite O-desmethylvenlafaxine to strongly inhibit serotonin and norepinephrine reuptake in the brain. The evidence also suggests that dopamine and norepinephrine behave in a co-transportational manner, due to the inactivation of dopamine by norepinephrine reuptake in the frontal cortex, an area of the brain largely lacking in dopamine transporters. This effect of SNRIs results in increased dopamine neurotransmission, in addition to the increases in serotonin and norepinephrine activity. Furthermore, because SNRIs are extremely selective, they have no measurable effects on other, unintended receptors, in contrast to monoamine oxidase inhibition. Pharmaceutical tests have determined that use of both SNRIs or SSRIs can generate significant anti-inflammatory action on microglia, as well.
AH-7921 (Doxylam) is an opioid analgesic drug selective for the μ-opioid receptor, having around 90% the potency of morphine when administered orally. It was discovered in the 1970s by a team at Allen and Hanburys located in the United Kingdom. The drug is considered a new psychoactive substance (NPS), a designation of compounds designed to mimic the effects controlled substances. It has also been sold on the internet since 2012 as a "research chemical". When sold online it may be called the alternative name doxylam, not to be confused with doxylamine. AH-7921 has never progressed to clinical trials. The DEA is not aware of any medical usage in the United States, and has not insisted the Health and Human Services department (HHS) to conduct any medical research of the substance's uses.
Sources: en.wikipedia.org
=== Medical === Indigenous healers in Africa use different parts of the locust bean tree for health benefits. In a survey conducted on healers in Togo, Parkia biglobosa was one of the highest cited plants used for treating hypertension. The tree was also one of two plants "listed as having real wound-healing properties in South-Western Nigeria, influencing the proliferation of dermal fibroblasts significantly." In a similar survey conducted in Guinea relating to their use of antimalarial plants, Parkia biglobosa was cited among those most often successfully used. In an analysis on the antibacterial properties of the plant, another study found that "these properties compare favourably with those of streptomycin, making it a potential source of compounds used in the management of bacterial infections."
=== Dollar Cravings === On August 18, 2014, Taco Bell launched a new value menu called Dollar Cravings. Replacing the old Why Pay More menu, Dollar Cravings featured thirteen food items all priced at a United States dollar. It was renamed "Cravings Value Menu", when prices were increased on some of the items. In April 2019, they introduced a "loaded nacho taco" for a dollar. As of January 2024, the company featured 10 items.
The siege of Coimbra in 1064 or the definitive conquest of Coimbra by Christian forces took place in 1064, from January to July; it ended on 9 July 1064, a Friday, when the king, Ferdinand I of Leon, captured the city from the Muslims. The city of Coimbra had previously been taken from the Christians by Almanzor (or al-Manṣūr) in 987. When the Fitna of al-Andalus broke out and the Umayyad Caliphate of Cordova fragmented into numerous taifa states, Dom Sesnando Davides, lord of Tentúgal proposed the conquest of the city to Ferdinand of Leon. Ferdinand thus began preparations for the campaign in December 1063, after receiving the remains of Saint Isidore of Seville in León. Before he moved against Coimbra however, he made a pilgrimage to Santiago de Compostela. Having prayed there before the tomb of the apostle, St. James of Compostela, for three days and made several donations to the church there, he departed accompanied by his wife Dona Sancha, his sons, the Bishop Crescónio of Santiago, Bishop Vistruário of Lugo, Bishop Suário of Mondonhedo, Bishop Sesnando of Portugal, the abbot Ariano of Cela Nova, abbot Pedro of Guimarães, and a large number of nobles. They advanced through a coastal road that linked Santiago de Compostela to Iria Flavia to Braga, Porto and Coimbra. They arrived before the walls of the city on 20 January 1064. The Muslim garrison fiercely resisted the Christian attacks. The supply situation of the Christians was not favourable and Ferdinand even pondered lifting the siege.
Radon is produced by the radioactive decay of radium-226, which is found in uranium ores, phosphate rock, shales, igneous and metamorphic rocks such as granite, gneiss, and schist, and to a lesser degree, in common rocks such as limestone. Every square mile of surface soil, to a depth of 6 inches (2.6 km2 to a depth of 15 cm), contains about 1 gram of radium, which releases radon in small amounts to the atmosphere. It is estimated that 2.4 billion curies (90 EBq) of radon are released from soil annually worldwide. This is equivalent to some 15.3 kilograms (34 lb). Radon concentration can differ widely from place to place. In the open air, it ranges from 1 to 100 Bq/m3, even less (0.1 Bq/m3) above the ocean. In the United States, the average outdoor radon level is estimated to be 15 Bq/m3 (0.4 pCi/L). In caves or ventilated mines, or poorly ventilated houses, its concentration climbs to 20–2,000 Bq/m3. Radon concentration can be much higher in mining contexts. Ventilation regulations instruct to maintain radon concentration in uranium mines under the "working level", with 95th percentile levels ranging up to nearly 3 WL (546 pCi 222Rn per liter of air; 20.2 kBq/m3, measured from 1976 to 1985). The concentration in the air at the (unventilated) Gastein Healing Gallery averages 43 kBq/m3 (1.2 nCi/L) with maximal value of 160 kBq/m3 (4.3 nCi/L). Radon mostly appears with the radium/uranium series (decay chain) (222Rn), and marginally with the thorium series (220Rn).
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.